(2-(trimethylammonium)ethyl)methanethiosulfonate has been researched along with 1-methyl-3-isobutylxanthine in 1 studies
Studies ((2-(trimethylammonium)ethyl)methanethiosulfonate) | Trials ((2-(trimethylammonium)ethyl)methanethiosulfonate) | Recent Studies (post-2010) ((2-(trimethylammonium)ethyl)methanethiosulfonate) | Studies (1-methyl-3-isobutylxanthine) | Trials (1-methyl-3-isobutylxanthine) | Recent Studies (post-2010) (1-methyl-3-isobutylxanthine) |
---|---|---|---|---|---|
143 | 0 | 17 | 5,148 | 5 | 279 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Snyder, PM | 1 |
1 other study(ies) available for (2-(trimethylammonium)ethyl)methanethiosulfonate and 1-methyl-3-isobutylxanthine
Article | Year |
---|---|
Liddle's syndrome mutations disrupt cAMP-mediated translocation of the epithelial Na(+) channel to the cell surface.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Biological Transport; Cells, Cultured; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Epithelium; Hypertension; Mesylates; Mutation; Rats; Rats, Inbred F344; Sodium; Sodium Channels | 2000 |